IGIrina Vladimirovna Galtseva

Irina Vladimirovna Galtseva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irina Vladimirovna Galtseva has a total of 308 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systematic Characterization of AML Cell Lines to Support Preclinical In Vitro CAR-T Research

    by Vassa D. Davydova, Anastasia A. Zotova, Nikolay M. Kapranov, Dmitry V. Dianov, Yulia O. Davydova, Tatiana A. Nenasheva, Irina Y. Zaichenko, Sergei D. Losev, Kseniia A. Nikiforova, Irina V. Galtseva, et al.

    The development of chimeric antigen receptor (CAR) T cell therapies for acute myeloid leukemia (AML) remains challenging, underscoring the need for reliable preclinical models. Although AML cell lines are widely used in CAR-T studies, their ability to reflect clinically relevant antigen expression patterns and functional characteristics of primary AML cells has not been systematically evaluated. We characterized nine AML cell lines (KG-1, HL-60, Kasumi-1, OCI-AML2, OCI-AML5, THP-1, U-937, MV4-11, and MOLM-13) as targets for in vitro CAR-T studies. We assessed the expression of established CAR-T target antigens (e.g., CLL1, CD33), cell lines similarity to minimal residual disease (MRD) cells and matched healthy monocytes from 161 AML patients, the expression of emerging AML-associated antigens (Siglec-6, CSF1R, and CD70), growth behavior, and susceptibility to non-specific killing by non-transduced T cells. AML cell lines demonstrated substantial heterogeneity in antigen expression with several cell lines showing antigen densities exceeding those observed in AML blasts. Several widely used lines, including U-937, were susceptible to non-transduced T-cell cytotoxicity, potentially confounding CAR-T functional assays and overestimating CAR-T activity in vitro. The examined parameters were integrated into a scoring framework to rank AML cell lines according to their suitability for in vitro CAR-T studies. Based on this framework and additional assay-related considerations, OCI-AML2, OCI-AML5, MV4-11, and MOLM-13 were identified as most suitable for in vitro evaluation of CAR-T products, particularly those targeting CD33 and CLL1. These findings may facilitate more informed selection of AML cell lines for preclinical development of CAR-T therapies for AML.

  • Open Access

    Copy-Number Alterations and Copy-Neutral Loss of Heterozygosity in Adult T-ALL: A Descriptive Study in Relation to Day +70 MRD

    by Natalya Risinskaya, Sofia Starchenko, Abdulpatakh Abdulpatakhov, Yulia Chabaeva, Olga Aleshina, Ekaterina Kotova, Tatiana Obukhova, Anna Yushkova, Olga Maiorova, Nikolay Kapranov, et al.

    Chromosomal microarray analysis (CMA) detects copy-number alterations and copy-neutral loss of heterozygosity (cnLOH), but the CMA landscape of adult T-ALL has been described in few cohorts. Day +70 measurable residual disease (MRD) is a surrogate marker of early treatment response, available only after induction. Thirty-nine adults with Ph-negative T-ALL on a single protocol underwent diagnostic CMA. Mosaic events were catalogued per chromosome and against a 57-gene panel and described in relation to day +70 MRD status (13 MRD-positive, 25 MRD-negative). The analysis is presented as descriptive without formal inference. Mosaic alterations were present in almost all patients, so groups differed in the amount rather than the presence of genomic change. Complex profiles (≥3 affected chromosomes) were seen in 46.2% of MRD-positive and 20.0% of MRD-negative patients. Biallelic 9p21.3 deletion occurred in both groups, whereas 9p cnLOH without deletion occurred predominantly in MRD-negative patients. Total cnLOH burden did not track with copy-number burden. Copy-number and copy-neutral events are mechanistically distinct and were not interchangeable here: 9p deletion and 9p cnLOH are separable by SNP array and should be reported separately rather than pooled. No association reached significance, although the cohort was too small to detect all but very large effects.

  • Open Access

    The Value of Bone Marrow Flow Cytometry for Diagnosis, Evaluation of Hematologic Response, and Monitoring of Non-Measurable Disease in AL Amyloidosis Patients

    by Nelli Aleksandrovna Kashchavtseva, I. G. Rekhtina, I. V. Galtseva, L. P. Mendeleeva

    BACKGROUND. In 8–20 % of patients with systemic AL amyloidosis (AL-A), a non-measurable disease is diagnosed which is characterized by low serum concentration of paraprotein and free light chains (FLCs). The standard immunochemical methods are not sufficiently robust in such clinical situation to evaluate the response to therapy and subsequent monitoring of the disease. AIM. To compare clinical and laboratory characteristics of AL-A patients with measurable and non-measurable diseases as well as to estimate the diagnostic value of multicolor flow cytometry of bone marrow (BM) in non-measurable AL-A. MATERIALS & METHODS. This prospective study enrolled 108 patients with newly diagnosed systemic AL-А, 20 (18.5 %) of them with a non-measurable disease (the difference between involved and uninvolved FLCs < 50 mg/L, paraprotein level < 10 g/L). All patients underwent clinical and laboratory examination including immunochemical analysis and 10-color flow cytometry of BM. RESULTS. In patients with non-measurable AL-A, severe cardiac failures occurred significantly less frequently (stage III: 16.7 % vs. 33.4 %; p = 0.03), whereas the rates of kidney and other organ involvements did not considerably differ. The median plasma cell (PC) count in non-measurable and measurable AL-A was 3.4 % and 5.2 %, respectively (p = 0.36) with the proportion of aberrant PCs in the total PC count being significantly lower in non-measurable disease (median 70.0 % vs. 92.2 %; p = 0.01). No correlation between the involved FLC concentration and the number of aberrant PCs was observed in non-measurable AL-A, while in measurable disease this correlation appeared to be significant (p = 0.003). The study demonstrated that the changes in aberrant PC clone by flow cytometry better correlated with the clinical response than with the changes of immunochemical parameters. Thus, the 5-year overall survival of patients with non-measurable and measurable AL-A did not differ (68 % and 61 %, respectively; p = 0.77). However, the 4-year clinical-progression-free (without vital organ dysfunction) survival was significantly lower in non-measurable disease, i.e., 23 % vs. 47 % (p = 0.04), which demonstrates that the standard immunochemical criteria alone used for response evaluation cannot provide sufficient control of the disease. CONCLUSION. Multicolor flow cytometry of BM is an effective additional method of diagnosis and monitoring of non-measurable AL-A disease, which allows to determine the tumor clone and objectively assess the therapy efficacy in cases when immunochemical methods appear to be limited. It seems to be advisable to regard flow cytometry as part of standard examination for this category of patients aiming to improve the accuracy of diagnosis and the evaluation of hematologic response.

  • Open Access

    Pattern of T-Lymphocyte Subpopulation in Patients with Cold Agglutinin Disease

    by Polina Igorevna Vasilchenkova, M. N. Finyakina, O. F. Nikulina, N. V. Tsvetaeva, S. M. Kulikov, I. V. Galtseva, E. A. Lukina

    BACKGROUND. Cold agglutinin disease (CAD) is an orphan hematologic disease characterized mainly by hemolytic anemia, increased titer of cold antibodies, and clonality of B-lymphocytes in peripheral blood or/and bone marrow. The role of T-cell population imbalance in CAD has not been studied due to the rarity of this disease and extreme heterogeneity of its clinical and laboratory manifestations. AIM. To analyze the pattern of T-lymphocyte subpopulation in CAD patients and to assess the information value of immune parameters for predicting the treatment efficacy and relapse risk. MATERIALS & METHODS. Over the period from 2020 to 2023, 128 patients with autoimmune hemolytic anemia were examined and treated at the National Research Center for Hematology, the CAD diagnosis was confirmed in 25 of them. The control group consisted of 57 healthy blood donors. RESULTS. Primary CAD patients showed significant decrease of naïve and central memory T-cells compared to similar subpopulations in donors. In 3 and 6 months after completion of immunosuppressive therapy with rituximab, CAD patients had a significant increase of T-helpers and cytotoxic T-lymphocytes as well as a decrease of T-regulatory cells. Among T-helper subpopulations, an increase in Th2 and Th17 cells was reported. The patients who achieved complete hematologic response prior to rituximab therapy, demonstrated a significant increase in Th22 cells. After 3 months of treatment, non-responders showed a drastic increase in cytotoxic T-lymphocytes followed by a decrease to baseline. CONCLUSION. The analysis of the phenotypic spectrum of T-cells demonstrated the difference between the count of naïve and central memory T-cells in CAD patients and healthy donors. This study revealed no significant association of these parameters with the response to immunosuppressive therapy. The only factor associated with achieving complete hematologic response to rituximab was a higher Th22 baseline level compared to donor population.

  • Open Access

    Immunophenotypic features of the tumor substrate of Waldenström’s macroglobulinemia

    by I. V. Galtseva, Гальцева И. В., Yu. A. Tsoy, Цой Ю. А., Yu. O. Davydova, Давыдова Ю. О., A. E. Grachev, Грачев А. Е., A. B. Vinnikova, Винникова А. Б., et al.

    Background. Waldenström’s macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with a heterogeneous tumor substrate. Methods for selection and characterizing WM tumor cells using multicolor flow cytometry vary in the literature. Since the choice of optimal gating strategy directly impacts diagnostic accuracy and tumor volume assessment, developing a unified approach is a pressing issue. Aim. To develop an optimal gating strategy for separating the tumor substrate in WM patients before initiating specific therapy and to study the immunophenotypic characteristics of each compartment. Materials and methods. The study included 60 patients (31 men and 29 women) with a median age of 61 years. Bone marrow was analyzed using multicolor flow cytometry. A panel of antibodies against CD19, CD20, CD22, CD27, CD38, CD45, CD138, immunoglobulin M, and the light chains of immunoglobulins κ and λ was used. Results. A unique gating strategy was proposed in the study, including the separation of the B-cell component, plasma cells (PCs), and intermediate lymphoplasmacytic cells (LPCs). Tumor B cells were detected in the bone marrow sample of 60 patients (100 %), tumor PCs in 53 (88 %), and LPCs in 45 (75 %). In all cases, tumor B cells and PCs demonstrated monoclonal restriction by immunoglobulin light chains (κ/λ) and immunoglobulin M expression. Tumor B cells, compared to normal B cells, had lower expression of CD19, CD20, CD22, and CD27 antigens. PCs differed from normal B cells by a higher density of CD20, CD45, and immunoglobulin M heavy chain antigen expression, as well as lower expression of CD38 and CD138. Conclusion. The three-component strategy proposed for research purposes allows for a detailed characterization of WM tumor clone heterogeneity. However, for routine clinical diagnosis, a two-component approach (B cells + PCs), based on the inclusion of LPCs in the PC-compartment, is sufficient. Despite the identified heterogeneity, in clinical practice, we recommend combining LPCs with PCs due to the similarity of their immunophenotypes and the lack of additional diagnostic value when analyzed separately. Multicolor flow cytometry is a valuable adjunctive diagnostic method for patients with suspected WM.

  • Open Access

    Gender- and Age-Related Changes in the Spectrum of the Differentiation Potential of Individual Colonies of Stromal Precursors from Human Bone Marrow

    by Irina Shipounova, Alena Dorofeeva, Tatiana Savvateeva, Kseniya Nikiforova, Nikolay Kapranov, Yuliya Davydova, Irina Galtseva, Anastasia Naumova, Alexandra Paderina, Olga Pokrovskaya, et al.

    Bone marrow (BM) mesenchymal stromal progenitors that give rise to almost all mature cells in the hematopoietic niche were studied. We analyzed the differentiation spectrum of individual colony-forming units of fibroblast (CFU-F) clones depending on the age and gender of the donor. Individual CFU-F clones (n = 292) were obtained from the BM samples of 19 donors (11 men, 8 women). The concentration of monopotent adipogenic precursors in the BM of men was significantly higher than that in the BM of women (15% ± 5% versus 4% ± 2%). Moreover, the concentration of monopotent adipogenic precursors in women’s BM had a clear negative correlation with age (R = −0.74), while, in men, it did not (R = −0.05). Younger donors of both genders had a higher proportion of monopotent adipogenic precursors; the proportion of precursors unable to differentiate increased markedly with age. All types of precursors revealed age- and gender-associated changes in the expression level of several genes. Both age and gender should be taken into account in studies concerning human stromal cells’ regenerative abilities. Alterations in the stromal precursors’ spectrum may impact the cellular composition of the bone marrow stromal microenvironment and explain the changes occurring in the regenerative potential with age and gender.

  • Experience with pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to C5 inhibitor therapy

    by Maria N. Finyakina, Финякина Мария Николаевна, O. F. Nikulina, Никулина О. Ф., I. V. Galtseva, Гальцева И. В., I. I. Mulina, Мулина И. И., Z. A. Ochirova, Очирова З. А., et al.

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematologic disorder whose pathogenesis is primarily driven by the formation of a cell clone (the PNH clone) lacking surface protective glycoproteins (CD55 and CD59), activation of the alternative complement pathway, and complement-mediated destruction of erythrocytes within blood vessels (intravascular hemolysis). This process underlies the main clinical manifestations of PNH – hemolytic anemia and thrombotic complications. The introduction of eculizumab, a C5 complement inhibitor, into clinical practice in 2007, which blocks the mechanism of intravascular hemolysis, revolutionized the course and prognosis of PNH. However, 30–45 % of patients continue to experience anemia and require replacement blood transfusions after 6 months or more of regular C5 inhibitor therapy. It has been established that the most common cause of a suboptimal treatment response is extravascular hemolysis, which is based on opsonization of PNH erythrocytes by C3b complement fragments followed by phagocytosis and degradation of these cells by macrophages in the liver and spleen. To suppress the mechanism of extravascular hemolysis, inhibitors of the proximal complement pathway have been developed, including the C3 inhibitor pegcetacoplan, which was registered in Russia in 2023 under the trade name Empaveli. The drug inhibits the activity of C3 and C3b complement components and thereby blocks the entire complement activation cascade, providing suppression of both intravascular and extravascular hemolysis. This article presents the first Russian experience of treating nine PNH patients with suboptimal response to C5 inhibitor therapy with pegcetacoplan. All nine patients demonstrated an average increase in hemoglobin levels of 25 g / L from baseline, achieving transfusion independence. The article also provides a detailed description of three clinical cases of particular interest.

  • Open Access

    Minimal residual disease monitoring using multicolor flow cytometry and allele-specific polymerase chain reaction for the MYD88 gene p.L265P mutation in patients with Waldenstrom’s macroglobulinemia

    by I. V. Galtseva, Гальцева И. В., Anastasiya B. Vinnikova, Винникова Анастасия Борисовна, A. E. Grachev, Грачев А. Е., A. A. Kulikov, Куликов А. А., Yu. A. Tsoy, Цой Ю. А., et al.

    Background. Waldenstrom’s macroglobulinemia (WM) is a rare indolent lymphoma characterized by bone marrow infiltration by lymphoplasmacytic cells and monoclonal immunoglobulin (Ig) M secretion. For primary diagnosis and assessment of remission depth, allele-specific polymerase chain reaction (AS-PCR) is also used to quantitatively assess the p.L265P mutation of the MYD88 gene with a sensitivity of 0.1 %. The treatment response is assessed according to the international NCCN (National Comprehensive Cancer Network) criteria, which are based on the regression of clinical symptoms and a decrease in serum monoclonal IgM concentration. However, this approach does not always reflect complete elimination of the tumor clone. Since the serum IgM concentration, determined by electrophoresis, can be maintained even in the absence of tumor cells in the bone marrow (up to 6 months), it is possible to use methods based on tumor clone characteristics, such as multicolor flow cytometry (MFC). The usefulness of minimal residual disease (MRD) monitoring using the MFC method, which is the standard for assessing remission depth in many other hematological malignancies, in WM has not been clearly determined. Aim. To compare the MRD-positive / negative status by MFC with the presence / absence of MYD88 gene p.L265P mutation by AS-PCR and clinical and laboratory characteristics of WM patients. Materials and methods. The study included 70 patients with WM who received treatment at the National Medical Research Center for Hematology between 2017 and 2025. The diagnosis was established in accordance with international criteria (2-IWWM (2nd International Workshop on Waldenstrom’s Macroglobulinemia) 2002, NCCN 2025) and Russian clinical guidelines. To assess the remission depth, 13-color MFC and AS-PCR to detect MYD88 gene p.L265P mutation in bone marrow aspirate were used. Results. Achieving MRD-negative status was statistically significantly more often associated with a lower baseline tumor burden (B-cell infiltration, IgM and β2-microglobulin levels) and higher hemoglobin and platelet counts. Regression of clinical manifestations (hepatosplenomegaly, B-symptoms) was not a clear predictor of achieving MRD-negative status. The study results confirmed the prognostic value of MRD monitoring by MFC for assessing the progression probability. The presence of MYD88 gene p.L265P mutation has not been confirmed as an unfavorable prognostic factor and continues to be studied. Conclusion. MFC is a universal method for both primary diagnosis and MRD monitoring in WM. Comprehensive MRD monitoring using MFC and AS-PCR for MYD88 gene mutation has prognostic value in WM. Achieving a double negative status (MFC– / MYD88–) is an objective marker of maximal complete remission.


  • Open Access

    Association of 12q21.32 cn‑LOH Affecting the KITLG p53 Response Element with Therapy Resistance in Acute Leukemia

    by Natalya Risinskaya, Sofia Starchenko, Yulia Chabaeva, Abdulpatakh Abdulpatakhov, Ekaterina Kotova, Valeriya Surimova, Dmitry Bessmertnyy, Anastasia Kashlakova, Anastasia Vasileva, Zalina Fidarova, et al.

    Background: The tumor suppressor p53 is a critical regulator of gene expression in cancer, acting through binding to specific p53 response elements (REs). One of key RE rs4590952 is found in the KITLG gene. Aims: This study aimed to precisely investigate the allelic variants of the SNP rs4590952 within patient groups with acute leukemia and to analyze their association with the disease and response to therapy. A specific objective was to determine the frequency and nature of regions of homozygosity encompassing the KITLG locus. Methods: The study cohort included: 37 patients with Ph-negative B-ALL, 38 with T-ALL, and 35 with de novo intermediate-risk AML. A reference group of 200 healthy individuals without oncohematological disorders was used for comparison. Chromosomal microarray analysis (CMA) was performed using the CytoScan™ HT-CMA. Statistical analysis was performed using Python 3.12.4 and SAS 9.4. Results: The allele frequency (AF) of the G allele of rs4590952 was 0.785 in the reference group. Among patients, the AF was 0.833 in T-ALL, 0.757 in B-ALL, and 0.743 in AML. The frequency of copy-neutral loss of heterozygosity (cn-LOH) at 12q21.32, which results in the GG genotype, was significantly higher in the T-ALL group (45%) compared to the reference group (27%) (OR=0.4; 95% CI: 0.2–0.9; p=0.02). A significant association between MRD-positive status and cn-LOH KITLG was found specifically in the T-ALL group (OR=11; 95% CI: 2–62; p=0.005). Cn-LOH KITLG was also significantly associated with poor chemotherapy response in AML (p=0.01). Summary: The GG genotype of the p53 response element in KITLG (rs4590952) frequently arises from acquired cn-LOH at 12q21.32, observed in 45% of T-ALL and 26-27% of other cases. This treatment-response marker, present irrespective of leukemic status, warrants further validation in expanded cohorts.

  • Open Access

    Characteristics and dynamics of the residual tumor clone determined by multicolor flow cytometry in Waldenstrom’s macroglobulinemia

    by A. B. Vinnikova, I. V. Galtseva, A. E. Grachev, K. A. Nikiforova, Y. A. Tsoy, S. E. Starchenko, S. M. Kulikov, S. A. Maryina, V. N. Dvirnyk, A. B. Sudarikov, et al.

    Background. Minimal residual disease (MRD), as determined by immunophenotyping, is an indicator of therapy response and a marker of relapse in many hematological diseases. There are some foreign publications devoted to the assessment of the residual tumor population using multicolor flow cytometry in Waldenstrom’s macroglobulinemia (WM). A characteristic feature of WM is the infiltration of bone marrow by two tumor populations from one tumor clone: clonal B-lymphocytes and clonal plasma cells. The study of these two aberrant populations was only possible using flow cytometry. In 90 % of WM cases, the L265P mutation of the MYD88 gene is detected: it is a diagnostic marker and is much less common in other lymphomas. Aim. To investigate the residual tumor clone characteristics in WM patients, their correlation with progression, assess the relationship between the monoclonal immunoglobulin M dynamics and MRD status, as well as between the presence of the MYD88 mutation at onset and the rate of tumor clone reduction. Materials and methods. Patients underwent immunophenotypic analysis of bone marrow cells at disease onset and at follow-up time points post-induction using multicolor flow cytometry. The following antigens were investigated for B-cells: surface CD19, CD22, CD20, CD45, and CD27, as well as cytoplasmic λ and κ immunoglobulin M antigens. For plasma cells, the following were assessed: surface CD38, CD138, CD27, CD45, CD81, and CD19, along with cytoplasmic λ and κ immunoglobulin M antigens. Standard methods of descriptive statistics and graphical visualization were used to analyze the results. To evaluate the dynamics of aberrant cell populations, multivariate statistical methods were employed, accounting for repeated measures within the same participants. The same methods were applied to study the association of the MYD88 gene mutation with the dynamics of these parameters. Results. Heterogeneity of the residual tumor clone was revealed, which could be represented by three variants of tumor populations: only aberrant B cells; only aberrant plasma cells; and populations of B- and plasma cells. Different reduction rates of residual aberrant B- and plasma cells were observed after the end of induction therapy: in the 1st month after treatment, the number of aberrant B cells decreased 1.4 times faster than plasma cells. The long-term persistence phenomenon of trace immunoglobulin M secretion after induction therapy even in MRD-negative patients was revealed (70 % cases). A relationship was noted between the presence of L265P mutation of the MYD88 gene at the disease onset and the number of residual B cells. In patients without a MYD88 gene mutation at the disease onset, MRD-negative B-cell status was achieved by the first month after the end of induction. No relationship was found between the presence / absence of the MYD88 gene mutation and the residual tumor plasma cell population. Patients with MRD-positive status in any combination (only aberrant B cells; only aberrant plasma cells; and populations of B- and plasma cells) demonstrated a higher probability of disease progression compared to the MRD-negative group. Conclusion. The use of multicolor flow cytometry to detect residual neoplastic B-cell and plasma cell populations provides additional insights into the depth of remission, the rate of tumor cell reduction, and the heterogeneity of the residual malignant clone.